Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 24;9(2):LMT31.
doi: 10.2217/lmt-2020-0008.

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer

Chung-Shien Lee  1   2 , Craig E Devoe  2 , Xinhua Zhu  2 , Joanna Stein Fishbein  3 , Nagashree Seetharamu  2
Affiliations

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer

Chung-Shien Lee et al. Lung Cancer Manag. .

Abstract

Background: Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data suggests that nutritional status may play a role in antitumor immunity.

Materials & methods: This retrospective study of 106 non-small-cell lung cancer patients who started checkpoint inhibitors between 2014 and 2017 at our institution assessed relationship of nutritional parameters to overall survival (OS) and progression-free survival.

Results: Mean age was 68.7 ± 9.2 years and 59.4% patients were male. On multivariate analysis for OS, hypoalbuminemia and significant weight loss were prognostic at p-values of 0.0005 and 0.0052, respectively. We noted a parabolic association between age and OS (p = 0.026, 0.0025).

Conclusion: In our study, some malnutrition parameters were associated with decreased OS. U-shape relationship between age and OS noted here warrants further evaluation.

Keywords: immunotherapy; malnutrition; non-small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure N Seetharamu has served on the advisory boards for Genentech and AstraZeneca in the last year. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Adjusted overall survival curves for initial significant weight loss and baseline albumin level status.
Figure 2.
Figure 2.. Predicted overall survival curves for various patient age profiles, holding serum albumin ≥3.5 g/dl and reported ≥5% weight loss within 6 months prior to immunotherapy initiation.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018). - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019). - PubMed
    1. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J. Immunother. Cancer 6(1), 8 (2018). - PMC - PubMed
    1. Brahmer J, Reckamp KL, Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015). - PMC - PubMed
    1. Ready N, Hellmann MD, Awad MM. et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J. Clin. Oncol. 37(12), 992–1000 (2019). - PMC - PubMed

LinkOut - more resources